10-QPeriod: Q3 FY2006

Cencora, Inc. Quarterly Report for Q3 Ended Jun 30, 2006

Filed August 8, 2006For Securities:COR

Summary

AmerisourceBergen Corporation (COR) reported its second-quarter results for fiscal year 2006, showcasing significant revenue growth and improved profitability. The company experienced a robust 15% increase in operating revenue, reaching $14.4 billion for the quarter, driven primarily by the Pharmaceutical Distribution segment. This growth reflects strong performance from key customers and the expanding specialty pharmaceutical business. Profitability also saw an upward trend, with net income rising 26% year-over-year to $119.5 million. Diluted earnings per share (EPS) increased by 29% to $0.58, demonstrating effective operational management and strategic initiatives. The company continued its aggressive share repurchase program, signaling confidence in its financial position and commitment to shareholder value. Additionally, strategic acquisitions in Canada and the UK are expanding AmerisourceBergen's geographic reach and service offerings, positioning it for continued growth in the global healthcare services market.

Key Highlights

  • 1Operating revenue for the quarter grew 15% to $14.4 billion, primarily driven by the Pharmaceutical Distribution segment.
  • 2Net income increased 26% year-over-year to $119.5 million.
  • 3Diluted earnings per share (EPS) rose 29% to $0.58, indicating improved profitability on a per-share basis.
  • 4The company completed several strategic acquisitions, including Trent Drugs (Wholesale) Ltd. in Canada and Brecon Pharmaceuticals Limited in the UK, expanding its international presence and service capabilities.
  • 5The Pharmaceutical Distribution segment's gross profit increased 17% year-over-year, benefiting from fee-for-service agreements and generic programs.
  • 6AmerisourceBergen continued its share repurchase program, buying back 8.6 million shares during the quarter for approximately $373.8 million.
  • 7A non-binding letter of intent was signed to combine PharMerica Long-Term Care business with Kindred Healthcare's institutional pharmacy business, aiming to create a new independent public company.

Frequently Asked Questions

Revenue growth was primarily driven by the Pharmaceutical Distribution segment, which saw a 15% increase in operating revenue. This growth was fueled by strong performance from key institutional and retail customers, continued growth in the specialty pharmaceutical business (ABSG), and contributions from recent acquisitions in Canada and the UK.

Profitability improved significantly. Net income increased by 26% to $119.5 million, and diluted earnings per share (EPS) grew by 29% to $0.58. This improvement reflects increased gross profit from higher revenues, effective cost management, and benefits from strategic initiatives.

The company completed several strategic acquisitions, including Trent Drugs (Wholesale) Ltd. (renamed AmerisourceBergen Canada Corporation) and Brecon Pharmaceuticals Limited. Additionally, AmerisourceBergen announced a non-binding letter of intent to combine its PharMerica Long-Term Care business with Kindred Healthcare's institutional pharmacy business, signaling a strategic shift in its long-term care operations.

AmerisourceBergen continued its share repurchase program, buying back approximately $373.8 million of its common stock during the quarter, demonstrating confidence in its financial health and commitment to returning value to shareholders. The company also maintained its quarterly cash dividend.